These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24118885)

  • 1. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
    Denison H; Nilsson C; Löfgren L; Himmelmann A; Mårtensson G; Knutsson M; Al-Shurbaji A; Tornqvist H; Eriksson JW
    Diabetes Obes Metab; 2014 Apr; 16(4):334-43. PubMed ID: 24118885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study.
    Denison H; Nilsson C; Kujacic M; Löfgren L; Karlsson C; Knutsson M; Eriksson JW
    Diabetes Obes Metab; 2013 Feb; 15(2):136-43. PubMed ID: 22950654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.
    Morentin Gutierrez P; Yates J; Nilsson C; Birtles S
    Pharmacol Res Perspect; 2019 Apr; 7(2):e00465. PubMed ID: 30899516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
    Floettmann E; Lees D; Seeliger F; Jones HB
    Toxicol Pathol; 2015 Apr; 43(3):376-83. PubMed ID: 25112279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
    Lin HV; Chen D; Shen Z; Zhu L; Ouyang X; Vongs A; Kan Y; Levorse JM; Kowalik EJ; Szeto DM; Yao X; Xiao J; Chen S; Liu J; Garcia-Calvo M; Shin MK; Pinto S
    PLoS One; 2013; 8(1):e54480. PubMed ID: 23336002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying.
    Ables GP; Yang KJ; Vogel S; Hernandez-Ono A; Yu S; Yuen JJ; Birtles S; Buckett LK; Turnbull AV; Goldberg IJ; Blaner WS; Huang LS; Ginsberg HN
    J Lipid Res; 2012 Nov; 53(11):2364-79. PubMed ID: 22911105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
    Meyers CD; Amer A; Majumdar T; Chen J
    J Clin Pharmacol; 2015 Sep; 55(9):1031-41. PubMed ID: 25854859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.
    Maciejewski BS; LaPerle JL; Chen D; Ghosh A; Zavadoski WJ; McDonald TS; Manion TB; Mather D; Patterson TA; Hanna M; Watkins S; Gibbs EM; Calle RA; Steppan CM
    Am J Physiol Gastrointest Liver Physiol; 2013 Jun; 304(11):G958-69. PubMed ID: 23558010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects.
    Enç FY; Ones T; Akin HL; Dede F; Turoğlu HT; Ulfer G; Bekiroğlu N; Haklar G; Rehfeld JF; Holst JJ; Ulusoy NB; Imeryüz N
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G482-9. PubMed ID: 19109408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).
    Barlind JG; Bauer UA; Birch AM; Birtles S; Buckett LK; Butlin RJ; Davies RD; Eriksson JW; Hammond CD; Hovland R; Johannesson P; Johansson MJ; Kemmitt PD; Lindmark BT; Morentin Gutierrez P; Noeske TA; Nordin A; O'Donnell CJ; Petersson AU; Redzic A; Turnbull AV; Vinblad J
    J Med Chem; 2012 Dec; 55(23):10610-29. PubMed ID: 23116186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice.
    Takemoto K; Fukasaka Y; Yoshimoto R; Nambu H; Yukioka H
    Physiol Rep; 2020 Aug; 8(15):e14542. PubMed ID: 32786057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion.
    Maciejewski BS; Manion TB; Steppan CM
    World J Gastrointest Pathophysiol; 2017 Nov; 8(4):161-175. PubMed ID: 29184702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people.
    Vazquez Roque MI; Camilleri M; Stephens DA; Jensen MD; Burton DD; Baxter KL; Zinsmeister AR
    Gastroenterology; 2006 Dec; 131(6):1717-24. PubMed ID: 17087952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
    Acosta A; Camilleri M; Shin A; Vazquez-Roque MI; Iturrino J; Burton D; O'Neill J; Eckert D; Zinsmeister AR
    Gastroenterology; 2015 Mar; 148(3):537-546.e4. PubMed ID: 25486131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
    Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
    Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.